Bexotegrast
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Bexotegrast
- Molecular weight
- 492.62
- Structure (SMILES)
- COCCN(CCCCC1=CC=C2CCCN=C2N1)CC[C@H](Nc1ncnc2ccccc12)C(=O)O
- bexotegrast
- Bexotegrast
- bexotegrast [INN]
- BEXOTEGRAST [USAN]
- bexotegrast inn
- bexotegrast usan
- pln 74809
- Pln 74809
- PLN 74809 [WHO-DD]
- pln 74809 who dd
- PLN-74809
- CAS registry numbers
- 2376257-44-0
- ChEMBL ID
- CHEMBL5095257
- InChIKey
- CWOFQJBATWQSHL-DEOSSOPVSA-N
- PubChem compound IDs
- 135390719
- FDA ingredient codes (UNII)
- QCV154PFT4
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- bexotegrast
- Type
- Synthetic organic
- Drug name stem
- -ast
Mechanisms of action
- Action
- Antagonist
- Action type
- Antagonist
- Target
- integrin, alpha V subunit
- Gene symbol
- ITGAV
- Protein identifier
- P06756
- Median affinity
- 5.47
- Affinity units
- pIC50
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Cholangitis, Sclerosing
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004268
- Subject identifier
- D015209
- Condition
- Pulmonary Fibrosis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009448
- Subject identifier
- D011658
- Condition
- Inflammation
- Highest recorded phase
- 2
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004268
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009448
- Condition identifier
- HP_0001395
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002771
- Condition identifier
- MONDO_0006502
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018646
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- Condition identifier
- MP_0001845
- NCT04072315
- NCT04396756
- NCT05621252
- NCT06097260
- NCT04480840
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 3
- Polar surface area
- 111.97
- Calculated partition coefficient (ALogP)
- 3.61
- Calculated partition coefficient (XLogP)
- 1.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 14
- Heavy atoms
- 36
- Molecular formula
- C27H36N6O3
- Monoisotopic mass
- 492.28488903
- Natural product
- No
- Recorded assays
- 14
- Active assays
- 14
Active assay types
- Confirmatory
Related records
Trials (6)
- Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
- Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
- Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
- Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
- Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
In development for (3)
- Idiopathic pulmonary fibrosis Phase 2
- Pulmonary fibrosis Phase 1
- Sclerosing cholangitis Phase 2